Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

NIH-funded clinical trial begins study of systemic allergic reactions to COVID-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

7 Apr 2021

Study lists five facts to know about antihistamines

If you are one of the millions of people worldwide suffering from allergies, you may take an antihistamine pill to ward off hives, sneezing and watery eyes.

6 Apr 2021

Scientists estimate the amount of peanut protein that will elicit an allergic reaction

An estimated 6 million Americans may suffer from peanut allergies. Tiny amounts of peanut protein can lead to hives, itching, tingling in the mouth, shortness of breath or nausea within minutes.

26 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

Study provides accurate data on allergic reactions related to mRNA COVID-19 vaccines

Almost immediately after the first mRNA-based COVID-19 vaccines were authorized for emergency use and were administered to individuals outside of clinical trials, reports of anaphylaxis--a life-threatening whole-body allergic reaction--raised widespread concerns among experts and the public.

10 Mar 2021

AI-mediated analysis of vaccinated patients affirms safety of SARS-CoV-2 vaccines

A new study provides a timely answer to many of these fears, by reporting on the results of an analysis of over 31,000 vaccine recipients with respect to immediate adverse effects, reported within 21 days, of the first and/or second doses of the vaccine.

25 Feb 2021

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.

10 Feb 2021

Study reveals new molecular mechanism linked to severe anaphylaxis

Anaphylaxis is a systemic allergic reaction that can affect the skin, the gastrointestinal tract, the respiratory system and the cardiovascular system.

9 Feb 2021

Commentary on severe allergic reaction to mRNA SARS-CoV-2 vaccines

A commentary by John M. Kelso, Division of Allergy, Asthma and Immunology, Scripps Clinic, published in the latest issue of the journal Vaccines, discusses anaphylactic reactions to these novel mRNA SARS-CoV-2/COVID-19 vaccines.

8 Feb 2021

Novel immunotherapy approach to revert the main hallmarks of cat allergy

Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system's allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy.

5 Feb 2021

Race may play an important role in children's food allergies

Black children have significantly higher rates of shellfish and fish allergies than White children, in addition to having higher odds of wheat allergy, suggesting that race may play an important role in how children are affected by food allergies, researchers at Ann & Robert H. Lurie Children's Hospital of Chicago, Rush University Medical Center and two other hospitals have found.

4 Feb 2021

Black children have significantly higher rates of shellfish and fish allergies than white children

Black children have significantly higher rates of shellfish and fish allergies than white children, confirming that race plays an important role in how children are affected by food allergies, researchers at Rush University Medical Center have found.

27 Jan 2021

Specific NSAIDs are metabolized by acyl-CoA synthetases leading to liver toxicity

Liver injury is a rare side effect of nonsteroidal anti-inflammatory drugs (NSAIDs), which are frequently used for daily pain control.

22 Jan 2021

Is your covid vaccine venue prepared to handle rare, life-threatening reactions?

As the rollout of covid-19 vaccines picks up across the U.S., moving from hospital distribution to pharmacies, pop-up sites and drive-thru clinics, health experts say it's vital that these expanded venues be prepared to handle rare but potentially life-threatening allergic reactions.

11 Jan 2021

COVID vaccines appear safe and effective, but key questions remain

The recent rollout of two newly authorized COVID-19 vaccines is a bright ray of hope at the pandemic's darkest hour.

23 Dec 2020

ACAAI releases guidance related to risk of allergic reactions to Pfizer-BioNTech COVID-19 vaccine

With the emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine by the FDA on December 11, 2020, and distribution beginning today, the American College of Allergy, Asthma and Immunology COVID-19 Vaccine Task Force recommends the following guidance related to risk of an allergic reaction on vaccination for those who receive the vaccine.

14 Dec 2020

FDA expands approved indication for influenza treatment to include post-exposure prevention

Today, the U.S. Food and Drug Administration expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of age and older after contact with an individual who has the flu.

23 Nov 2020

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

23 Nov 2020

Allergy charities encourage parents, teachers to ‘Check It, Don’t Chance It’ to safeguard allergic children

To mark Allergy Awareness Week (19-25 October), two leading allergy charities are urging parents and teachers to ‘Check It, Don’t Chance It’ to ensure pupils and young adults with allergies are safe in schools.

21 Oct 2020

Powerful antimicrobial molecules engineered from toxic proteins in wasp venom

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom.

12 Oct 2020